Cyclin-mediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer.
Anticancer Res
; 29(10): 3769-75, 2009 Oct.
Article
em En
| MEDLINE
| ID: mdl-19846907
ABSTRACT
BACKGROUND:
Celecoxib and other non-steroidal anti-inflammatory drugs (NSAIDs) are being evaluated in the prevention of bladder and other cancers. Here we investigate molecular effects of celecoxib independent of cyclooxygenase (COX)-2 expression levels in urothelial carcinoma of the bladder. MATERIALS ANDMETHODS:
Low-grade RT-4 and high-grade UM-UC-3 bladder cancer cells were treated with 0-50 muM celecoxib. Growth, cell cycle and apoptosis were measured by crystal violet elution and flow cytometry. Western analysis was performed for COX-2, Rb, cyclin B1/D1, and phospho-cyclin B1/D1. COX-2 induction was achieved with phorbol ester.RESULTS:
Celecoxib inhibited growth of RT-4 and UM-UC-3, with G(1) cell cycle arrest and altered cyclin B1/D1 expression in RT-4, whereas Rb up-regulation occurred in UM-UC-3. Apoptosis occurred in both cell lines.CONCLUSION:
Celecoxib induces G(1) cell cycle arrest in low- and high-grade bladder cancer by different pathways. This heterogeneous molecular response supports combination approaches to prevention and treatment.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirazóis
/
Sulfonamidas
/
Neoplasias da Bexiga Urinária
/
Fase G1
/
Ciclina D1
/
Ciclina B1
Limite:
Humans
Idioma:
En
Revista:
Anticancer Res
Ano de publicação:
2009
Tipo de documento:
Article
País de afiliação:
Estados Unidos